Trial Profile
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and PREVNAR 13® (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 17 Mar 2018 Results published in the Vaccine.
- 05 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2012 Planned End Date changed from 1 Mar 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.